FDA To Decide On APRI's ED Drug, KURA Nails It, MBRX Dynamic, GLMD Awaits ARREST

Kura Oncology Inc. (KURA) gained 11.67% on Thursday, following encouraging preliminary results from its phase II clinical trial of lead product candidate, Tipifarnib, in patients with head and neck squamous cell carcinomas with HRAS mutations. Tipifarnib is expected to move into registrational trial later this year.

from RTT - Biotech http://ift.tt/2HkeRQA
via IFTTT